GSMA: WRC-19 Opens Door To Exciting New 5G Services
22.11.2019 17:30:00 EET | Business Wire | Press release
The GSMA today welcomed the international spectrum treaty adopted by the World Radiocommunication Conference 2019 (WRC-19), which will unlock the potential for game-changing 5G services around the world. The conference, which has just concluded in Sharm el-Sheikh, Egypt, has identified much-needed spectrum for a broad range of new ultra-high-speed and ultra-low latency consumer, business and government services.
Innovative 5G services that rely on the almost instantaneous delivery of large amounts of data are now possible through the identification of millimetre wave frequencies in the 26 GHz, 40 GHz and 66 GHz ranges. These include virtual and augmented reality applications, remote control of industrial robots, autonomous vehicles, as well as entertainment services, such as downloading 4K movies in seconds.
International coordination supported by the International Telecommunication Union (ITU) at WRCs is essential to achieving widespread spectrum harmonisation for mobile services. The global identification of mmWave frequencies will help unlock economies of scale needed to accelerate the delivery of innovative and affordable 5G services around the world. A wide range of industries – including manufacturing, transport, healthcare and education – are set to benefit.
“WRC-19 has brought the mobile industry a step closer to making the full power of 5G something everyone can experience,” said Mats Granryd, Director General, GSMA. “Countries struck the right balance in opening up groundbreaking possibilities for 5G while protecting existing radio services worldwide. The mobile industry’s goal going into WRC-19 was to identify enough 5G spectrum to deliver long-lasting socio-economic benefits. WRC-19 delivered on this goal, and also secured a pathway to 5G’s future success in the agenda for WRC-23.”
As mobile continues to evolve, so do the spectrum requirements. WRC-19 recognised this by setting an agenda for the next WRC in 2023 that will consider identification of additional mid- and low-frequency bands.
Mid-frequency spectrum in the 3 GHz range (from 3.3-4.2 GHz) is already being used for commercial 5G services, providing a good balance of coverage and capacity. Increasing the amount of globally harmonised spectrum in this frequency range at WRC-23 would boost 5G network performance, bring down deployment costs and drive significant economic benefits.
To help spread the benefits of 5G to rural areas and accelerate the Internet of Things (IoT) revolution, the GSMA is also supporting efforts to identify more spectrum below 1 GHz at WRC-23 to improve 5G coverage.
“We want the benefits of 5G to be available to everyone. With more than 5 billion mobile subscribers globally, previous generations of mobile technology have connected more people more quickly than any technology in history,” added Mats Granryd. “WRC plays an essential role in driving the global economies of scale that allow mobile services to transform people’s lives and national economies.”
-ENDS-
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators and nearly 400 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.
For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191122005284/en/
Contact information
Media Contacts:
For the GSMA
Alia Ilyas
+44 (0)7970 637622
ailyas@gsma.com
GSMA Press Office
pressoffice@gsma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
